- Home
- SNTI vs ADAP Comparison
SNTI vs ADAP Comparison
Compare SNTI & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- ADAP
- Stock Information
- Founded
- SNTI 2016
- ADAP 2008
- Country
- SNTI United States
- ADAP United Kingdom
- Employees
- SNTI N/A
- ADAP N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- SNTI Health Care
- ADAP Health Care
- Exchange
- SNTI Nasdaq
- ADAP Nasdaq
- Market Cap
- SNTI 85.3M
- ADAP 73.1M
- IPO Year
- SNTI N/A
- ADAP 2015
- Fundamental
- Price
- SNTI $3.35
- ADAP $0.30
- Analyst Decision
- SNTI Strong Buy
- ADAP Strong Buy
- Analyst Count
- SNTI 1
- ADAP 5
- Target Price
- SNTI $12.00
- ADAP $1.83
- AVG Volume (30 Days)
- SNTI 226.4K
- ADAP 775.4K
- Earning Date
- SNTI 05-06-2025
- ADAP 05-13-2025
- Dividend Yield
- SNTI N/A
- ADAP N/A
- EPS Growth
- SNTI N/A
- ADAP N/A
- EPS
- SNTI N/A
- ADAP N/A
- Revenue
- SNTI N/A
- ADAP $178,032,000.00
- Revenue This Year
- SNTI N/A
- ADAP N/A
- Revenue Next Year
- SNTI N/A
- ADAP $69.81
- P/E Ratio
- SNTI N/A
- ADAP N/A
- Revenue Growth
- SNTI N/A
- ADAP 195.34
- 52 Week Low
- SNTI $1.52
- ADAP $0.20
- 52 Week High
- SNTI $16.94
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- SNTI 45.79
- ADAP 54.77
- Support Level
- SNTI $3.10
- ADAP $0.30
- Resistance Level
- SNTI $3.50
- ADAP $0.31
- Average True Range (ATR)
- SNTI 0.39
- ADAP 0.02
- MACD
- SNTI -0.07
- ADAP 0.01
- Stochastic Oscillator
- SNTI 20.36
- ADAP 80.51
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.